A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Mirikizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-2
- Sponsors Eli Lilly
- 04 Feb 2019 Planned End Date changed from 9 Apr 2020 to 10 Jun 2020.
- 04 Feb 2019 Planned primary completion date changed from 27 Jan 2020 to 18 Mar 2020.
- 12 Sep 2018 Planned End Date changed from 20 Apr 2020 to 9 Apr 2020.